Monomeric bimetal hydroxycitric acid (HCA) compounds are provided. The subject compounds include a divalent metal (X) bonded to the carboxylic acids of C2 and C3 and a monovalent metal (Y) bonded to the carboxylic acid of C1. Also provided are methods of preparing the subject compounds from a dimeric starting material (e.g., X.sub.3(HCA).sub.2) which include acidifying the dimer to produce a monomeric intermediate which is subsequently neutralized with YOH base. Methods of alleviating at least one symptom associated with a target disease or condition in a subject are provided. Also provided are compositions including the subject monomeric bimetal HCA compounds which find use in a variety of therapeutic applications.

The present invention relates to a transition metal organic framework, comprising: a transition metal oxide having antibacterial or antifungal properties; and an organic compound having at least one hydrophilic functional group, wherein the organic compound is bound to the transition metal oxide to surround the transition metal oxide and the hydrophilic functional group is placed toward the outside of the transition metal organic framework.

Catechol metal complex compounds of formula (I)

##STR00001##

are colored and can be used to give color to surfactant compositions. Detergents containing these catechol metal complex compounds do not stain the textile even after repeated use.

A multi-component detergent, including at least two components, that is contained in a container having at least two chambers, wherein a first component K1 is a first liquid composition, containing at least one catechol metal complex compound of formula (I)

##STR00001##

and at least one free catechol compound of formula (II) or the salt thereof

##STR00002##

with the proviso that the catechol compound of formula (II) and the salt thereof are different from the compounds of formula (I), and a second component K2 is a second liquid composition, containing at least one surfactant. The present invention further relates to the use of the multi-component detergent for removing bleachable stains and a method for washing textiles using the multi-component detergent.

The present disclosure relates to a preparation method of a methionine-metal chelate, and the methionine-metal chelate, which is prepared by first reacting Ca(OH).sub.2 and methionine and adding metal chloride salts, can be used as feeds and feed additives.

The invention discloses use of a uranium-containing compound as a scintillator. The uranium-containing compound is a uranium-containing organic-inorganic hybrid compound or a uranium-containing inorganic compound. The uranium-containing organic-inorganic hybrid compound is a uranium-containing organic carboxylate or a uranium-containing organophosphate. The uranium-containing inorganic compound is a uranium-containing non-metallate, a uranium-containing metal salt, or a uranium-containing halide. The invention discloses the uranium-containing organic-inorganic compound or the uranium-containing inorganic compound having intrinsic scintillating ability, and provides a new concept and method for the development of (organic-inorganic, inorganic) scintillators of various chemical compositions and configurations with the uranium element.

The invention relates to a novel radiopharmaceutical that inhibits the prostate-specific membrane antigen (iPSMA), containing hydrazinonicotinamide (HYNIC) as a critical chemical group in increasing in the lipophilicity of the molecule for binding to the hydrophobic sites of the PSMA, combined with the conventional use of HYNIC as a chelating agent for radiometal .sup.99mTc, in which the ethylenediaminetetraacetic acid (EDDA) is used to complete the coordination sphere of the radiometal. The novel radiopharmaceutical .sup.99mTc-EDDA/HYNIC-iPSMA detects, with high affinity and sensitivity in vivo, the overexpressed PSMA protein in prostate cancer cells using SPECT molecular imaging techniques in nuclear medicine. The aim of the invention is to provide a novel specific radiopharmaceutical (radiopharmaceutical for molecular targets) for SPECT, with high sensitivity for the detection of tumours with overexpression of PSMA.

Compounds are described and characterized that bind guanine quadruplexes of DNA or RNA. Binding data and inhibition of growth data of five cancer cell lines are presented.

Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.

The present invention relates to a stable pharmaceutical composition of tetrofosmin or pharmaceutically acceptable salts thereof. It also relates to a lyophilized non-radioactive kit which upon reconstitution with .sup.99mTc-pertechnetate solution gives a stable .sup.99mTc-tetrofosmin radiopharmaceutical composition. It also provides process for the preparation of said radiopharmaceutical compositions and their use in diagnostic imaging procedures. The compositions provide desirable technical attributes such as stability, high radiochemical purity (RCP) and desired bio-distribution.